Researchers proposed a CAR T strategy designed to overcome tumor heterogeneity and reduce systemic toxicity by localizing EpCAM-targeting bispecific T cell engagers at the tumor site. The approach described in the Singapore Immunology Network and collaborating institutions focuses on a key challenge in EpCAM-directed therapies: EpCAM is expressed on normal tissues as well as tumors. The concept uses CAR T cells engineered to secrete anti-EpCAM bispecific engagers in a local manner, aiming to limit off-tumor activity while maintaining the ability to engage tumor-resident immune kill mechanisms. This is positioned as a way to address EpCAM’s ubiquitous expression barrier without relying on fully systemic targeting. For CAR T developers, the publication reflects an ongoing shift toward next-generation construct designs—particularly those that seek to tune exposure profiles, manage target antigen safety liabilities, and improve functional persistence across variable antigen landscapes. The strategy also contributes to the broader CAR architecture discussion around “armored” or secretion-based mechanisms to broaden applicability beyond single-antigen constraints.